Literature DB >> 33481783

Contribution of viral infection to risk for cancer in systemic lupus erythematosus and multiple sclerosis.

Deborah K Johnson1, Kaylia M Reynolds1, Brian D Poole1, Matthew D Montierth1, Vera M Todd1, April Barnado2, Mary F Davis1,3.   

Abstract

Patients with autoimmune disorders (AD) have altered cancer risks compared to the general population. Systemic lupus erythematosus and multiple sclerosis lead to a heightened risk for hematological malignancies and decreased risk for breast, ovarian, and prostate malignancies. Often patients with autoimmune disease have dysregulated antiviral immune responses, including against oncogenic viruses. To uncover the relationship between viral incidence and cancer risk in the context of autoimmune disease, we extracted electronic health records (EHR) from Vanderbilt University. ICD-9/10 codes and laboratory values were collected for hematological, lung, anal-vaginal, thyroid, hepatobiliary, bladder, prostate, and breast cancers; and viruses including Epstein Barr virus (EBV), Human papilloma virus (HPV), and Hepatitis A/B/C (Hep). Only viral infections that led to a physician visit or laboratory test were entered into the EMR; therefore, only clinically relevant cases were noted and considered positive in this study. The relationship between virus infection and cancer in an SLE cohort (SLE-cases n = 2,313, and SLE-controls n = 5,702) and an MS cohort (MS-case n = 7,277, MS-control n = 7,277) was examined by multilinear logistic regression. Viral infection was strongly associated with increased risk for cancer overall. SLE and MS patients were more susceptible to all viral infections. MS patients trended toward increased risk for cancers overall, while decreased risk for hormone-based cancers in SLE patients non-significantly reduced their risk for overall cancer. Both SLE and MS patients had increased clinically relevant EBV infection, which was associated with risk for hematological cancers. Preventing viral infections by vaccination may be especially helpful in controlling risk for cancer in SLE and MS patients.

Entities:  

Year:  2021        PMID: 33481783      PMCID: PMC7822541          DOI: 10.1371/journal.pone.0243150

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  37 in total

1.  Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.

Authors:  Catherine Schairer; Ruth M Pfeiffer; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2017-11-24       Impact factor: 7.396

2.  Increased risk of cancer in patients with systemic lupus erythematosus.

Authors:  T Pettersson; E Pukkala; L Teppo; C Friman
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

Review 3.  Prostate cancer in systemic lupus erythematosus.

Authors:  S Bernatsky; R Ramsey-Goldman; C Gordon; A E Clarke
Journal:  Int J Cancer       Date:  2011-03-29       Impact factor: 7.396

4.  Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus.

Authors:  H H L Tsang; N J Trendell-Smith; A K P Wu; M Y Mok
Journal:  Lupus       Date:  2009-11-06       Impact factor: 2.911

Review 5.  Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.

Authors:  Hans Helmut Niller; Hans Wolf; Janos Minarovits
Journal:  Autoimmunity       Date:  2008-05       Impact factor: 2.815

6.  Breast cancer in systemic lupus.

Authors:  S Bernatsky; R Ramsey-Goldman; M Petri; M B Urowitz; D D Gladman; P R Fortin; E Ginzler; J Romero-Diaz; C Peschken; S Jacobsen; J G Hanly; C Gordon; O Nived; E H Yelin; D Isenberg; A Rahman; S-C Bae; L Joseph; T Witte; G Ruiz-Irastorza; C Aranow; D Kamen; G Sturfeldt; W D Foulkes; J E Hansen; Y St Pierre; P Chrétien Raymer; B Tessier-Cloutier; A E Clarke
Journal:  Lupus       Date:  2016-09-30       Impact factor: 2.911

Review 7.  Epstein-Barr virus and multiple sclerosis.

Authors:  Daniela Pohl
Journal:  J Neurol Sci       Date:  2009-04-10       Impact factor: 3.181

8.  Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood.

Authors:  Uk Yeol Moon; Su Jin Park; Sang Taek Oh; Wan-Uk Kim; Sung-Hwan Park; Sang-Heon Lee; Chul-Soo Cho; Ho-Youn Kim; Won-Keun Lee; Suk Kyeong Lee
Journal:  Arthritis Res Ther       Date:  2004-05-07       Impact factor: 5.156

Review 9.  A systematic review of the incidence and prevalence of cancer in multiple sclerosis.

Authors:  Ruth Ann Marrie; Nadia Reider; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Per Soelberg Sorensen; Stephen C Reingold; Gary Cutter
Journal:  Mult Scler       Date:  2014-12-22       Impact factor: 6.312

Review 10.  Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation.

Authors:  Andreas Lossius; Jorunn N Johansen; Øivind Torkildsen; Frode Vartdal; Trygve Holmøy
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

View more
  1 in total

1.  Hematological malignancies in systemic lupus erythematosus: clinical characteristics, risk factors, and prognosis-a case-control study.

Authors:  Yuqi Zhang; Wei Li; Panpan Zhang; Jinyan Guo; Jinlei Sun; Jiameng Lu; Shengyun Liu
Journal:  Arthritis Res Ther       Date:  2022-01-03       Impact factor: 5.156

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.